No dedicated treatment currently available for cocaine addiction
TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that its recently launched collaboration with Clearmind Medicine Inc. (“Clearmind”) (CNSX:CMND.CN), (OTC:CMNDF), (FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, resulted in the filing of a provisional patent application related to treating cocaine addiction.
Read more at globenewswire.com